Alogliptin
Spezifikationen
850649-61-5CAS-Nummer
821-899-3EG-Nummer
2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrileIUPAC-Name
C18H21N5O2Chemische Formel
339.4 g/molMolekulargewicht
Alogliptin; 850649-61-5; alogliptina; alogliptine; vipidia; alogliptinum; JHC049LO86; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; HSDB 8203; CHEBI:72323; DTXSID90234130; 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile; alogliptin tartrate; 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; RefChem:57142; A10BH04; DTXCID90156621; Benzonitrile, 2-((6-((3R)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl)-; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; Alogliptin [INN]; MFCD09833196; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile; Benzonitrile,2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-; UNII-JHC049LO86; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; Trelagliptin Impurity 30; 1347001-80-2; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; Alogliptin; Alogliptin (Standard); ALOGLIPTIN [MI]; ALOGLIPTIN [VANDF]; ALOGLIPTIN [WHO-DD]; SCHEMBL121028; CHEMBL376359; GTPL6319; HY-A0023AR; orb1300993; orb3141143; SCHEMBL29352995; BDBM16285; HY-A0023A; ZSBOMTDTBDDKMP-OAHLLOKOSA-N; ALBB-038593; EX-A5446; EBC-26650; MSK177669; AKOS025149226; CCG-267914; CCG-267915; CS-1617; DB06203; FA17319; 2-[[6-[(3R)-3-amino-1-piperidyl]-3-methyl-2,4-dioxo-pyrimidin-1-yl]methyl]benzonitrile; NCGC00386215-02; NCGC00386215-04; NCGC00386215-05; AC-26300; AS-19582; SY077741; A4038; NS00071194; SW219186-1; EN300-6482025; F468425; Q4734170; BRD-K83003151-001-02-2; BRD-K83003151-001-03-0; BRD-K83003151-057-02-4; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrileSynonyme
Produkte, die Alogliptin enthalten
VIPDOMET 12,5 MG/850 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPDOMET 12,5 MG/850 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPIDIA 6,25 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPIDIA 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPIDIA 12,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPDOMET 12,5 MG/850 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIncresync 25 mg/30 mg comprimidos recubiertos con peliculaIncresync 12,5 mg/30 mg comprimidos recubiertos con peliculaAlogliptin
Seite 1 von 2